Resistance Development with Tenofovir/FTC vs. AZT/3TC
In a comparative clinical trial, patients receiving tenofovir/FTC were less likely to develop resistance mutations during virologic failure than were those receiving AZT/3TC.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)